HOLD affirmed; tiered add framework converts binary "add at levels" into event-driven execution scaffolding
Maintain HOLD at defensive income sizing. The rating verdict is correct based on prior decision history showing Hold + pre-committed triggers preserves alpha better than binary Overweight/Underweight swings for this archetype. The tiered add framework—deploying ~1/3 on golden cross, another 1/3–1/2 on either $94.49 breakout with volume or $91.38–$91.78 pullback, reserving dry powder for $88.67 flush—converts the binary "add at specified levels" into event-driven execution scaffolding that respects both the aggressive catalyst thesis (revenue acceleration, ablation +29.5%, FY27 guidance raise, Cornerstone optionality) and the conservative risk management (bearish RSI divergence, MACD histogram negative, Sep 1 distribution on 18.84M shares). Hard stop at $86.45. 3.12% dividend yield provides income carry while waiting. Q2 FY27 print is the decisive re-evaluation catalyst.
| Position | Action |
|---|---|
| 50/200 SMA golden cross confirmed | Deploy ~1/3 of intended new capital as structural starter |
| Breakout above $94.49 with rising volume OR pullback to $91.38–$91.78 Bollinger midline zone | Add another 1/3–1/2 of intended new capital |
| Flush to $88.67 or breakout retest materializes | Reserve remaining dry powder for this asymmetric re-entry |
| Daily close below $86.45 (50 SMA) | Hard stop; evaluate core position separately |
| Revenue ≥5% YoY AND forward EPS supports $6.00+ AND guidance constructive AND stock holds >$88.69 | UPGRADE to Overweight |
| Revenue <3% YoY OR forward EPS cut >5% OR guidance softens materially OR stock closes below $88.69 on >20M volume | DOWNGRADE to Underweight with 15-25% trim |
MDT is a quality compounder at a confirmed inflection point: Q1 FY27's +29.5% cardiac ablation growth and FY26 revenue re-acceleration to +8.4% justify a 14.55x forward P/E multiple that the market is underpricing versus trailing 24.96x, with structural tailwinds from Boston Scientific weakness and a $700M Cornerstone robotics deal.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | 91.78 | bullish |
| 50 SMA | 86.45 | bullish |
| 200 SMA | 88.67 | bullish |
| MACD | 1.64 | neutral |
| MACD Signal | 1.89 | neutral |
| MACD Histogram | -0.24 | bearish |
| RSI | 61.80 | neutral |
| RSI Peak (Aug 19) | 75.05 | bullish |
| Bollinger Upper Band | 94.49 | neutral |
| Bollinger Middle Band | 91.38 | bullish |
| Bollinger Lower Band | 88.27 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: 50/200 SMA golden cross imminent
Then: Initiate ~1/3 position as structural starter
↩ rebuts: “Bears question whether the acceleration is sustainable or a one-quarter beat”
· concedes: The 70% EPS growth implied by the forward multiple is aggressive and requires Q1 to be the start of a multi-quarter compounding cycle, not a one-off—if Q2 FY27 in-lines, the forward multiple compresses fast; Momentum chase on a 3-month basis is real; tactical traders who bought the lows have gains but new entrants need to size appropriately using the $91.38–$91.78 pullback zone; Robotics deals have integration risk; the $700M Cornerstone deal is forward-looking, not yet contributing, and must execute
MDT is the wrong stock at the wrong price right now — the setup is for a pullback to $91.38-$86.45, with asymmetric risk favoring bears who need only one thesis element to fail.
· concedes: Q1 FY27 beat was real; Cardiac ablation growth of +29.5% was impressive; MDT is a fine company, not a bad one; Defensive rotation is a real macro theme; Sentiment and institutional flow are unambiguously constructive; Golden cross, when it prints, will be technically constructive; TTM P/E at 24.96x is not cheap but has compressed historically
→ vs conservative: Bearish RSI divergence (94.13 price with RSI rolling 75 to 62) and negative MACD histogram represent textbook tape-reading that misses the point—divergences resolve either via price collapse or sideways consolidation while fundamentals reset; the latter is occurring here given confirmed revenue inflection, ablation growth, guidance raise, and imminent golden cross
→ vs conservative: Forward P/E gap (14.55 vs TTM 24.96 implying 70% earnings growth) is justified because the market is pricing multi-quarter compounding of 8.4% revenue base into a $5B+ net income franchise with visible margin expansion; sell-side is catching up to management's telegraph
→ vs conservative: Historical execution risk argument is backward-looking thinking that has underperformed this entire rally; management raised full-year guidance while raising the bar, which is the most aggressive signal from med-tech's most conservative guidance regime
→ vs neutral: Waiting for confirmation through golden cross or pullback to 88-91 zone is the most dangerous advice—Q1 print was the confirmation; institutional bid is already real and in the tape; anyone waiting for 91.38 pullback will chase breakout at 94+ or miss the run to 98
→ vs neutral: Cornerstone Robotics $700 million deal is not tuck-in noise or integration risk—it's a strategic decision to position MDT as active consolidator in surgical robotics where ISRG earns its premium multiple; execution unlocks multiple re-rating from 15x toward 20x
| bullish |
| ATR | 2.27 | neutral |
| VWMA(20) | 92.06 | bullish |
Support: 91.38 · 88.67 · 86.45 · 88.27 | Resistance: 94.49 · 94.13
MDT has rallied approximately +11.9% from $83.21 (Jul 24) to $93.10 (Sep 3), with a verified wide-range bullish candle on Sep 3 (Open 93.04, Low 90.96, Close 93.10, Volume 7.41M). The price structure shows bullish alignment: 93.10 > 10 EMA 91.78 > 200 SMA 88.67 > 50 SMA 86.45. A bearish RSI divergence is present (RSI declined from 75.05 to 61.80 while price reached $93.10), and MACD histogram flipped negative (-0.24). The 50 SMA is rising rapidly from 85.93 to 86.45 and on track for a golden cross above the 200 SMA within approximately one week. Key resistance is at 94.13 (Aug 19 intraday high) and 94.49 (Bollinger upper band). Tactical bias favors pullback entries to 91.38–91.78 over chasing the upper band, with stop below 90.00 and invalidation on daily close below 88.67.
Market Cap
$119.17 B
Shares Outstanding
1,280,177,293
Beta
0.574
Dividend Yield
3.12%
P/E (TTM)
24.96x
Forward P/E
14.55x
PEG Ratio
1.82
P/B (Price/Book)
2.41x
EPS (TTM)
$3.73
Forward EPS
$6.40
52-Week Range
$73.31 – $106.33
50-Day MA
$86.20
200-Day MA
$89.74
Implied Current Price
$93.10
TTM Revenue
$37.54 B
TTM Gross Profit
$24.51 B
TTM EBITDA
$10.40 B
TTM Net Income
$5.23 B
Gross Margin
65.3%
Operating Margin
19.5%
Net Margin
13.9%
EBITDA Margin
27.7%
FY2022 Revenue
$31.2 B
FY2023 Revenue
$32.4 B
FY2024 Revenue
$32.4 B
FY2025 Revenue
$33.5 B
FY2026 Revenue
$36.4 B
FY2026 YoY Growth
+8.4%
FY2022 Net Income
$3.76 B
FY2023 Net Income
$3.68 B
FY2024 Net Income
$4.66 B
FY2025 Net Income
$4.80 B
FY2026 Net Income
$5.23 B
FY2026 Operating CF
$7.33 B
FY2026 Free Cash Flow
$5.43 B
FCF Margin
14.9%
FY2026 Capex
$1.90 B
FY2026 Dividends Paid
$3.64 B
FY2026 Share Repurchases
$1.04 B
FCF Dividend Coverage
1.49x
Total Assets
$93.03 B
Total Debt
$27.96 B
Cash & ST Investments
$9.22 B
Net Debt
$25.95 B
Stockholders' Equity
$49.46 B
Goodwill & Intangibles
$52.73 B
Tangible Book Value
-$3.27 B
Net Debt / EBITDA
~2.5x
Debt/Equity
58.2%
Q4 FY2026 Revenue
$9.81 B
Q4 FY2026 Diluted EPS
$0.96
Q4 FY2026 Op Cash Flow
$2.57 B
Q4 FY2026 Net Debt Change
-$914 M
Q4 FY2026 Tax Rate
31.4%
FY2026 Restructuring/M&A Charges
$249 M
ROE
~10.6%
Effective Tax Rate
~21%
Strengths
Concerns
Medtronic delivered FY2026 revenue of $36.4B (+8.4% YoY), breaking out of a multi-year ~3.5% growth band, with TTM EBITDA of $10.4B and net income of $5.23B; the company is de-leveraging (net debt fell $914M in Q4 to $25.95B) and returning cash via dividends (3.12% yield) while shrinking its share count 4% over two years. The stock trades at a wide valuation gap (24.96x trailing vs 14.55x forward P/E), implying the market is pricing in ~70% earnings growth into FY27/28 that requires validation through upcoming quarterly results, with Q1 FY27 earnings as the next major catalyst.
Macro: Market pricing decisively higher-for-longer Fed; September cut essentially priced out (1% implied), December cut only 12% implied. US recession probability by end-2026 is 7% and falling. Defensive rotation underway from tech/AI into healthcare and Dividend Aristocrats. BSX competitor weakened by cyberattack. ISRG and JNJ near 52-week highs and fully valued, leaving MDT as the valuation-anchored large-cap med-tech entry point.